FDA
approval
· 2012-02-02
FDA Approved: JANUMET XR — Original Application (Merck Sharp & Dohme LLC)
Summary
FDA approved JANUMET XR, a new extended-release formulation combining sitagliptin and metformin hydrochloride for type 2 diabetes mellitus.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
ORIG AP for JANUMET XR (SITAGLIPTIN AND METFORMIN HYDROCHLORIDE)